---
title: "Longeveron Inc. (LGVN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LGVN.US.md"
symbol: "LGVN.US"
name: "Longeveron Inc."
industry: "Biotechnology"
datetime: "2026-05-20T07:42:28.948Z"
locales:
  - [en](https://longbridge.com/en/quote/LGVN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LGVN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LGVN.US.md)
---

# Longeveron Inc. (LGVN.US)

## Company Overview

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [longeveron.com](https://longeveron.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.68)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 303 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -45.35% |  |
| Net Profit YoY | 12.30% |  |
| P/B Ratio | 1.23 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 19714990.22 |  |
| Revenue | 1216000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -135.18% | E |
| Profit Margin | -1844.49% | E |
| Gross Margin | 66.33% | A |
| Revenue YoY | -45.35% | E |
| Net Profit YoY | 12.30% | C |
| Total Assets YoY | 1.74% | C |
| Net Assets YoY | -6.59% | D |
| Cash Flow Margin | 81.67% | C |
| OCF YoY | -45.35% | E |
| Turnover | 0.06 | E |
| Gearing Ratio | 24.44% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Longeveron Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-45.35%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "12.30%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.23",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "19714990.22",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1216000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-135.18%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1844.49%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "66.33%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-45.35%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "12.30%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.74%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-6.59%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "81.67%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-45.35%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.06",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "24.44%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.88 | 172/386 | - | - | - |
| PB | 1.23 | 115/386 | 1.54 | 1.31 | 1.15 |
| PS (TTM) | 16.21 | 187/386 | 11.54 | 8.77 | 8.02 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 50% |
| Hold | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.67 |
| Highest Target | 10.45 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LGVN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LGVN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LGVN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LGVN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**